Results 181 to 190 of about 394,130 (296)

MEN1 Deficiency Drives Lung Cancer Progression via Activation of MMP10‐Mediated Angiogenesis

Cancer Science, EarlyView.
MEN1 deficiency promotes JunD‐mediated upregulation of MMP10 expression, which cleaves pro‐HB‐EGF and activates endothelial EGFR. This triggers the PI3K/Akt and MEK/ERK signaling pathways, thereby driving angiogenesis and tumor progression. MMP10 inhibitor treatment blocks this cleavage, suppresses EGFR signaling, and thereby delays malignant ...
Chengyu Wei, Xiangyu Liu, Shimin Hu, Xiaodie Shen, Yingli Liu, Xinxin Qin, Ye Zhou, Jianqi Zheng, Bingke Tian, Jingfang Hong, Yongxia Song, Di Wang, Linlin Peng, Jinxia Ding, Fang Wang, Hui Zhang, Shihao Zhang, Huan Qiu   +17 more
wiley   +1 more source

Author Correction: ZDHHC9 promotes osteosarcoma progression via KRAS-associated enhancement of the RAS/MAPK signaling pathway. [PDF]

Sci Rep
Li Z, Li J, Wu Y, Luo Y, Zheng J, Shi J.
europepmc   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Multi-Omics Integration Identifies FGF1 as a Diagnostic Biomarker and RAS-MAPK-Driven Pathogenic Factor in Osteoarthritis. [PDF]

J Inflamm Res
Yan Y, Wang C, Zhang M, Jiang X, Cheng W.   +4 more
europepmc   +1 more source

Hyperglycemia induces PFKFB3 overexpression and promotes malignant phenotype of breast cancer through RAS/MAPK activation. [PDF]

World J Surg Oncol, 2023
Cheng X, Jia X, Wang C, Zhou S, Chen J, Chen L, Chen J.   +6 more
europepmc   +1 more source

Daraxonrasib and Beyond: Pan‐RAS Inhibition, Resistance, and Next‐Generation Strategies

Cancer Science, EarlyView.
ABSTRACT RAS proteins have long been considered difficult therapeutic targets, but allele‐selective inhibitors established the clinical tractability of mutant RAS. Daraxonrasib (RMC‐6236), an oral pan‐RAS inhibitor, has now extended this concept by targeting multiple mutant and wild‐type RAS proteins.
Ryo Honda
wiley   +1 more source

Dusp6 attenuates Ras/MAPK signaling to limit zebrafish heart regeneration

Development, 2018
M. Missinato, Manush Saydmohammed, Daniel A. Zuppo, K. Rao, Graham W. Opie, B. Kühn, M. Tsang   +6 more
semanticscholar   +1 more source

Clinical and Genetic Profile of One Molecularly Confirmed and One Clinically Suspected Case of LZTR1‐Related Noonan Syndrome

Clinical Genetics, EarlyView.
This study illustrates the phenotypic variability of LZTR1‐related Noonan syndrome type 10 in two pediatric patients, including presentations without congenital heart defects. The findings emphasize the importance of whole‐exome sequencing and longitudinal re‐evaluation of variants of uncertain significance in achieving accurate diagnosis.
Karolina Skrzyńska, Barbara Kalina‐Faska, Ewa Błaszczyk, Aneta Gawlik‐Starzyk   +3 more
wiley   +1 more source

ZDHHC9 promotes osteosarcoma progression via KRAS-associated enhancement of the RAS/MAPK signaling pathway. [PDF]

Sci Rep
Li Z, Li J, Wu Y, Luo Y, Zheng J, Shi J.
europepmc   +1 more source

RAS-MAPK syndromes - a Clinical and Molecular Investigation

, 2009
The RAS-MAPK syndromes are a group of clinically and genetically related disorders, characterized by cardiac defects, facial dysmorphism, cutaneous abnormalities and neurocognitive impairment. The pathogenesis is dysregulation of the RAS-MAPK pathway, and several genes within the pathway are involved.
openaire   +1 more source